Glen Eagle Advisors’s Relmada Therapeutics RLMD Stock Holding History

Glen Eagle Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-25	Closed	-$655	–	1051
2021 Q3	$655	Hold	25	–	–	﹤0.01%	1007
2021 Q2	$800	Hold	25	–	–	﹤0.01%	977
2021 Q1	$880	Hold	25	–	–	﹤0.01%	946
2020 Q4	$802	Hold	25	–	–	﹤0.01%	920
2020 Q3	$941	Hold	25	–	–	﹤0.01%	854
2020 Q2	$1.12K	Hold	25	–	–	﹤0.01%	807
2020 Q1	$853	Hold	25	–	–	﹤0.01%	766
2019 Q4	$975	Buy	+25	New	+$760	﹤0.01%	833

Other funds holding RLMD

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Glen Eagle Advisors's RLMD Position: Q4 2021 in Review

Glen Eagle Advisors sold out of Relmada Therapeutics (RLMD) in Q4 2021, closing a stake of 25 shares — an estimated $655 sold.

Glen Eagle Advisors first reported a position in RLMD in Q4 2019 and held it in 8 quarters. The position peaked at $1.12K in Q2 2020. 97 funds tracked by Wall St. Rank hold RLMD as of Q4 2021.

Glen Eagle Advisors reported no remaining Relmada Therapeutics position as of Q4 2021 after selling out during the quarter.
Glen Eagle Advisors sold 25 Relmada Therapeutics shares in Q4 2021, an estimated $655.
Glen Eagle Advisors first reported a position in Relmada Therapeutics in Q4 2019 and held it in 8 quarters.
Glen Eagle Advisors's Relmada Therapeutics position peaked at $1.12K in Q2 2020.
97 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2021.

Based on Glen Eagle Advisors's 13F filing for Q4 2021, filed 13 Aug 2024.